

Lab Resource: Stem Cell Line

Establishment of a human iPSC line (IISHDOi001-A) from a patient with McArdle disease



María del Carmen Ortuño-Costela^{a,b,c,d}, Nathalie Rodríguez-Mancera^a, Marta García-López^a, Francisco Zurita-Díaz^{a,b,c,d}, Ana Moreno-Izquierdo^{d,e}, Alejandro Lucía^{d,f}, Miguel Ángel Martín^d, Rafael Garesse^{a,b,c,d}, M. Esther Gallardo^{a,b,c,d,*}

^a Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Spain

^b Instituto de Investigaciones Biomédicas “Alberto Sols”, (UAM-CSIC) Madrid, Spain

^c Centro de Investigación Biomédica en Red (CIBERER), Madrid, Spain

^d Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain

^e Servicio de Genética, Hospital 12 de Octubre, Madrid, Spain

^f Universidad Europea de Madrid, Spain

ARTICLE INFO

Article history:

Received 18 July 2017

Accepted 20 July 2017

Available online 28 July 2017

ABSTRACT

Human iPSC line IISHDOi001-A was generated from fibroblasts of a patient with McArdle disease harbouring the mutation, c.148C>T; p.Arg50Ter, in the *PYGM* gene. Reprogramming factors Oct3/4, Sox2, Klf4, and c-Myc were delivered using Sendai virus.

© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Resource table

Unique stem cell line identifier	IISHDOi001-A
Alternative name(s) of stem cell line	MA5622-FiPS4F1
Institution	Instituto de Investigación Sanitaria Hospital 12 de Octubre, i+12
Contact information of distributor	Dr. M. Esther Gallardo egallardo@iib.uam.es
Type of cell line	iPSC
Origin	Human
Additional origin info	Sex: female
Cell source	Human fibroblasts
Method of reprogramming	Sendai virus
Genetic modification	NO
Type of modification	N/A
Associated disease	McArdle disease
Gene/locus	Gene <i>PYGM</i> : c.148C>T; p.Arg50Ter
Method of modification	N/A
Name of transgene or resistance	N/A
Inducible/constitutive system	N/A
Date archived/stock date	June 2017
Cell line repository/bank	N/A
Ethical approval	Patient informed consent was obtained. This study was reviewed and approved by the Institutional Ethical Committee of the "Instituto de Investigaciones Biomédicas Alberto Sols", CSIC-UAM, 406 329 1.

Resource utility

McArdle disease is a disorder of carbohydrate metabolism inherited in an autosomal recessive way, associated with mutations in the *PYGM* gene. Patients with this disease experience exercise intolerance including, sometimes, rhabdomyolysis and myoglobinuria. The line IISHDOi001-A will be very useful for modelling this disease and searching for therapeutic approaches.

Resource details

The generation of the human iPSC line, IISHDOi001-A, was performed using non-integrative Sendai viruses containing the reprogramming factors Oct3/4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007). For this purpose, fibroblasts from a patient with McArdle disease were employed. These fibroblasts harboured the most prevalent mutation among the Caucasian population, located in the *PYGM* gene (c.148C>T; p.Arg50Ter) (Nogales-Gadea et al., 2016). The presence of this mutation in the iPSCs was confirmed (Fig. 1A). IISHDOi001-A iPSC colonies displayed a typical ES-like colony morphology and growth behavior (Fig. 1B) and they stained positive for alkaline phosphatase activity (Fig. 1C). We confirmed the clearance of the vectors and the exogenous reprogramming factor genes by RT-PCR after twelve culture passages (Fig. 1D). The endogenous expression of the pluripotency associated transcription factors *OCT4*, *SOX2*, *KLF4*, *NANOG*, *CRIP1* and *REX1* was evaluated by quantitative real time polymerase chain reaction (qPCR) (Fig. 1E). Immunofluorescence analysis revealed expression of transcription factors OCT4, NANOG, SOX2 and surface markers SSEA3,

* Corresponding author at: Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.

E-mail address: egallardo@iib.uam.es (M.E. Gallardo).




Fig. 1. Molecular and functional characterization of the IISHDOI001-A iPSC line.

SSEA4, TRA-1-60 and TRA-1-81 characteristics of pluripotent ES cells (Fig. 1F). The iPSC line has been adapted to feeder-free culture conditions and displays a normal karyotype (46, XX) after more than

twenty culture passages (Fig. 1G). We also confirmed by DNA fingerprinting analysis that the line IISHDOI001-A was derived from the patient's fibroblasts. In addition, the line was confirmed by PCR

analysis to be mycoplasma-negative (Fig. 1H). Finally, the capacity of the generated iPSC line to differentiate into the three germ layers (endoderm, mesoderm and ectoderm) was tested *in vitro* using an embryoid body based assay (Fig. 1I).

Materials and methods

Reprogramming of McArdle fibroblasts into iPSCs

Human McArdle fibroblasts harbouring the mutation p.Arg50Ter in the *PYGM* gene were reprogrammed using the CytoTune-iPS 2.0 Sendai reprogramming kit following the instructions of the manufacturer. IISHDOi001-A was maintained and expanded both on feeder and feeder-free layers as described in Galera et al., 2016.

Phosphatase alkaline analysis

The iPSC line IISHDOi001-A was seeded on a feeder layer plate. After one week, direct phosphatase alkaline activity was determined using the phosphatase alkaline blue membrane substrate solution kit (Sigma, AB0300) (Table 1).

Mutation analysis

Total DNA from patient's fibroblasts and iPSCs was extracted using a standard phenol-chloroform protocol. Subsequently, a PCR was carried out with the primers listed in Table 2. Following PCR amplification, direct sequencing of amplicons was performed in an ABI 3730 sequencer (Applied Biosystems).

qPCR analysis

Total mRNA was isolated using TRIZOL and 1 µg was used to synthesize cDNA using the QuantiTect RT cDNA synthesis kit. One microliter of the reaction was used to quantify by qPCR the expression of the endogenous pluripotency associated genes (*OCT4*, *SOX2*, *KLF4*, *NANOG*, *CRIPTO* and *REX1*). Primers are listed in Table 2 (Aasen et al., 2008). All the expression values were normalized to the *GAPDH* gene. Plots are representative of at least three independent experiments.

Karyotype analysis

Karyotype analyses were carried out using cells with more than twenty culture passages. Briefly, cells were treated with 10 µg/mL of Colcemid (Gibco) for 90 min at 37 °C, trypsinized, treated with hypotonic solution KCl 0.075 M, and fixed with Carnoy's fixative. Cells were then dropped on a microscope glass slide and dried. Metaphase cells were G banded using Wright staining. At least 20 metaphases were karyotyped.

Immunofluorescence analysis

Cells were grown on 0.1% gelatin-coated 35 mm culture plates (81,156, Ibdidi), fixed with 4% paraformaldehyde for 30 min at RT and permeabilized using TBS + (0.1% Triton X-100 in Tris-buffered saline, TBS) for 45 min. Then the cells were incubated in TBS + + (3% donkey serum, 0.3% Triton X-100 in TBS) for 2 h at RT. Primary antibodies were applied overnight at 4 °C. Secondary antibodies for 2 h at RT. Nuclei were stained with DAPI (Sigma, 28718-90-3). All the antibodies are listed in Table 2.

In vitro differentiation assay

The *in vitro* pluripotency capacity of the line IISHDOi001-A was tested by spontaneous embryoid body differentiation. The protocol we have used has been described in detail by Galera et al., 2016.

Table 1
Characterization and validation.

Classification	Test	Result	Data
Morphology	Photography	Normal	Fig. 1 panel B
Phenotype	Immunocytochemistry	Positive for the pluripotency markers: SSEA3, SSEA4, TRA-1-81, TRA-1-60, OCT4, NANOG, SOX2	Fig. 1 panel F
	Flow cytometry	N/A	
	Gene expression (qPCR)	Positive for the pluripotency markers <i>OCT4</i> , <i>KLF4</i> , <i>SOX2</i> , <i>CRIPTO</i> , <i>NANOG</i> , <i>REX1</i>	Fig. 1 panel E
Genotype	Alkaline phosphatase activity	Positive	Fig. 1 panel C
	Karyotype (G-banding) and resolution	46, XX	Fig. 1 panel G
		Resolution 450–500	
Identity	Microsatellite PCR (mPCR)	N/A	
	STR analysis	8 loci, all matched (D2S1338, D7S820, D8S1179, D13S317, D19S433, D21S11, VWA, amelogenin)	Submitted in archive with journal
Mutation analysis (IF APPLICABLE)	Sequencing	Confirmation of the mutation: <i>PYGM</i> c.148C>T; p.Arg50Ter	Fig. 1 panel A
	Southern Blot OR WGS	N/A	
Microbiology and virology	Mycoplasma	Negative	
	Sendai virus silencing	Virus silenced	Fig. 1 panel H
Differentiation potential	Embryoid body formation and directed differentiation	Positive for: smooth muscle actin (SMA), β -tubulin (Tuj1) and alpha-fetoprotein (AFP)	Fig. 1 panel D
Donor screening (OPTIONAL)	HIV 1 + 2 Hepatitis B, Hepatitis C	N/A	Fig. 1 panel I
Genotype additional info (OPTIONAL)	Blood group genotyping	N/A	
	HLA tissue typing	N/A	

Table 2
Reagents details.

Antibodies used for immunocytochemistry/flow-cytometry			
	Antibody	Dilution	Company Cat# and RRID
Pluripotency markers	Mouse anti-TRA-1-81	1:150	Millipore Cat# MAB4381, RRID: AB_177638
	Mouse anti-TRA-1-60	1:150	Millipore Cat# MAB4360, RRID: AB_11211864
	Rabbit anti-SOX2	1:100	Thermo Fisher Scientific Cat# PA1-16968, RRID: AB_2195781
	Mouse anti-SSEA4	1:10	Millipore Cat# MAB4304, RRID: AB_177629
	Rat anti-SSEA3	1:20	Abcam Cat# ab16286, RRID: AB_882700
	Goat anti-NANOG	1:25	R and D Systems Cat# sc-5279, RRID: AB_628051
	Mouse anti-OCT4	1:100	Santa Cruz Biotechnology Cat# sc-5279, RRID: AB_628051
Differentiation markers	Mouse anti- β tubulin isotype III	1:300	Sigma-Aldrich Cat# T8660, RRID: AB_528427
	Mouse anti- AFP	1:300	Sigma-Aldrich Cat# WH000174M1, RRID: AB_1839587
	Mouse anti- SMA	1:400	Sigma-Aldrich Cat# A2547, RRID: AB_476701
Secondary antibodies	Cy TM 2-conjugated AffiniPure Donkey Anti-Goat IgG (H + L)	1:50	Jackson ImmunoResearch Labs Cat# 705-225-147, RRID: AB_2307341
	Cy TM 2-conjugated AffiniPure Goat Anti-Mouse IgG, Fcy Subclass 2b specific	1:50	Jackson ImmunoResearch Labs Cat# 115-225-207, RRID: AB_2338749
	Cy TM 2-conjugated AffiniPure Goat Anti-Rabbit IgG (H + L)	1:50	Jackson ImmunoResearch Labs Cat# 111-225-144, RRID: AB_2338021
	Cy TM 3-conjugated AffiniPure Goat Anti-Rat IgM, μ chain specific	1:250	Jackson ImmunoResearch Labs Cat# 112-165-075, RRID: AB_2338249
	Cy TM 3-conjugated AffiniPure Goat Anti-Mouse IgG, Fcy Subclass 3 specific	1:250	Jackson ImmunoResearch Labs Cat# 115-165-209, RRID: AB_2338698
	Cy TM 3-conjugated AffiniPure Donkey Anti-Mouse IgM, μ chain specific	1:250	Jackson ImmunoResearch Labs Cat# 715-165-020, RRID: AB_2340811
	Goat anti-mouse IgG (H + L), Alexa Fluor 488	1:500	Thermo Fisher Scientific Cat# A-11029, RRID: AB_2534088
Primers	Target	Forward/Reverse primer (5'-3')	
Pluripotency markers (qPCR)	<i>Endo-KLF4</i>	AGCCTAAATGATGGTGTGGT/TTGAAAACCTTGGCTTCCTTGT	
	<i>Endo-OCT4</i>	GGGTTTTGGGATAAGTTCCTCA/GCCCCACCTTTGTGTT	
	<i>Endo-SOX2</i>	CAAAAATGGCCATGCAGGTT/AGTTGGGATCGAACAAGCTATT	
	<i>REX1</i>	CCTGCAGCGGAAATAGAAC/GCACACATAGCCATCACATAAGG	
	<i>CRIP1</i>	CGGAAGTGTGACGACGATGT/GGGCAGCCAGGTGTCTATG	
	<i>NANOG</i>	ACAACCTGGCCGGAAGAATAGCA/GGTTCCAGTCGGGTTTCC	
House-Keeping Genes (qPCR)	<i>GAPDH</i>	GCACCGTCAAGGCTGAGAAC/AGGGATCTCTCTCTGGAA	
	<i>PGY1</i>	CAAATCAGTGTGGTGGCT/CCTTCTCATAGTAGTGCTG	
Targeted mutation analysis/sequencing			
Virus silencing	SeV	GGTACTAGGTGATATCGAGC/ACCAGACAAGAGTTAAGAGATATGTATC	
	KOS	ATGCACCCTACGACGTGAGCCG/ACCTTGACAATCTGATGTGG	
	Klf4	TTCTGTCATGCCAGGAGGCC/AATGTATCGAAGGTGCTCAA	
	c-Myc	TAACCTACTAGCAGGCTGTGCG/TCCACATACAGTCCTGGATGATGATG	
STR analysis	D2S1338	[6-FAM] CCAGTGGATTGGAACAGA/ACCTAGCATGGTACCTGCAG	
	D7S820	[6-FAM] TGTATAGTTTGAACGAATAACG/CTGAGGTATCAAAAACAGAGG	
	D8S1179	[6-FAM] TTTTGTATTTTATGATGTGACATTCG/CGTAGCTATAATTAGTTCATTTTCA	
	D13S317	[6-FAM] ACAGAACTCTGGGATGTGGA/GCCCAAAAAGACAGACAGAA	
	D19S433	[6-FAM] CCTGGGCAACAGAATAAGAT/TAGGTTTTTAAGGAACAGGTGG	
	D21S11	[6-FAM] GTGAGTCAATCCCCAAG/GTTGTATTAGTCAATGTTCTCC	
	VWA	[6-FAM] CCCTAGTGGATGATAAGAATAATC/GGACAGATGATAAATACATAGGATGGATGG	
Mycoplasma detection	Amelogenin	[6-FAM] CCCTGGGCTCTGTAAGAATAAGT/ATCAGAGCTTAACTGGGAAGCTG	
	MGSO	TGACCATCTGCTACTCTGTAACTC/GAGGTTAACAGAGTGACAGATGGTGA	
	GPO-3	GGGAGCAACAGGATTAGATACCTC/AGGGTATCTAATCTGTTTCTCC	

DNA fingerprinting analysis

For DNA fingerprinting analysis the markers D13S317, D7S820, VWA, D8S1179, D21S11, D19S433, D2S1338 and amelogenin for sex determination have been amplified by PCR and analyzed by ABI PRISM 3100 Genetic analyzer and Peak Scanner v3.5 (Applied Biosystems) (Table 2).

Mycoplasma detection

Mycoplasma detection was performed by PCR analysis using 1 mL of the cell culture supernatant (3 days culture at 90% confluence). Primers used are specified in Table 2. The 300 bp band represents that the sample is positive for mycoplasma (positive control, C+). The band at 570 bp is an internal control to discard the inhibition of the polymerase.

Author disclosure statement

There are no competing financial interests in this study.

Acknowledgments

We are very grateful to Beatriz Moreno Moreno for her technical assistance. This work was supported by grants from: 1) the “Fondo de Investigación Sanitaria, Instituto de Salud Carlos III”: PI10/0703, PI13/00556 and PI16/00789 to RG and PI15/00484 to MEG cofunded by FEDER, 2) from the “Centro de Investigación Biomédica en Red en Enfermedades Raras” (CIBERER): grants 13-717/132.05 and ER16P3AC717 to RG and 3) “Comunidad Autónoma de Madrid” (grant number S2010/BMD-2402 to RG). MDCOC receives grant support from CIBERER and FZD from the Ministerio de Educación, Cultura y Deporte (FPU13/00544). MEG is supported by a “Miguel Servet contract” (CP16/00046) from ISCIII-MINECO-Spain/FEDER-EU.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.scr.2017.07.020>.

References

- Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilić, J., Pekarik, V., Tiscornia, G., Edel, M., Boué, S., Izpisua Belmonte, J.C., 2008. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. *Nat. Biotechnol.* 26 (11), 1276–1284.
- Galera, T., Zurita, F., González-Páramos, C., Moreno-Izquierdo, A., Fraga, M.F., Fernández, A.F., Garesse, R., Gallardo, M.E., 2016. Generation of a human iPSC line from a patient with Leigh syndrome. *Stem Cell Res.* 16 (1), 63–66.
- Nogales-Gadea, G., Godfrey, R., Santalla, A., Coll-Cantí, J., Pintos-Morell, G., Pinós, T., Arenas, J., Martín, M.A., Lucia, A., 2016. Genes and exercise intolerance: insights from McArdle disease. *Physiol. Genomics* 48 (2), 93–100.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131 (5), 861–872.